menu
    • menu

    Company profile for Neurogene

    NEW Drugs in Dev: 3
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 year...
    Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene,

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NeurogeneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    535 W 24th Street, 5th Floor New York, NY 10011
    Telephone
    Telephone
    1-877-237-5020
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neurogene.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/neurogene/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neurogene Sets 2026 Milestones for NGN-401 in Rett Syndrome
    Neurogene Sets 2026 Milestones for NGN-401 in Rett Syndrome

    12 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260112556591/en/Neurogene-Announces-Recent-Achievements-and-Anticipated-2026-Key-Milestones-for-NGN-401-a-Potential-Best-in-Class-Gene-Therapy-for-Rett-Syndrome

    BUSINESSWIRE
    12 Jan 2026
    Share Share
    Neurogene To Join 44Th J.P. Morgan Healthcare Conference
    Neurogene To Join 44Th J.P. Morgan Healthcare Conference

    05 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260105973729/en/Neurogene-to-Participate-in-the-44th-Annual-J.P.-Morgan-Healthcare-Conference

    BUSINESSWIRE
    05 Jan 2026
    Share Share
    Neurogene Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)
    Neurogene Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)

    04 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251204721853/en/Neurogene-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    04 Dec 2025
    Share Share
    Neurogene Unveils Q3 2025 Financials And Recent Developments
    Neurogene Unveils Q3 2025 Financials And Recent Developments

    13 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251113825408/en/Neurogene-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Recent-Updates

    BUSINESSWIRE
    13 Nov 2025
    Share Share
    Neurogene Reports Positive Data from NGN-401 Gene Therapy Trial
    Neurogene Reports Positive Data from NGN-401 Gene Therapy Trial

    12 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112150450/en/Neurogene-Reports-Positive-Interim-Data-in-Pediatric-Cohort-from-NGN-401-Gene-Therapy-Trial-for-Rett-Syndrome

    BUSINESSWIRE
    12 Nov 2025
    Share Share
    Neurogene Initiates NGN-401 Gene Therapy Trial For Rett Syndrome
    Neurogene Initiates NGN-401 Gene Therapy Trial For Rett Syndrome

    06 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251106135659/en/Neurogene-Announces-First-Participant-Dosed-in-Embolden-Registrational-Trial-of-NGN-401-Gene-Therapy-for-Rett-Syndrome

    BUSINESSWIRE
    06 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search